



COCHRANE RENAL GROUP

A REVIEW GROUP OF THE COCHRANE COLLABORATION

This booklet contains information about: -

- How we can help you
- The Review process
- List of Cochrane Renal Group reviews, protocols and titles
- Upcoming workshops and meetings
- Title registration form

We look forward to working with you.

Cochrane Renal Group Editorial Team



Endorsements: Asia Pacific Society of Nephrology, International Pediatric Nephrology Association, International Society of Nephrology, Kidney Health Australia, National Kidney Foundation

Introduction

Thank you for becoming a member of the Cochrane Renal Group. As a new member you will receive a Cochrane Renal Group pen (as a way to say thanks), regular newsletters, notices about upcoming meetings and issues relevant to our group. There is no obligation as a member to anything, however, you can contribute in several ways.

- Conducting a systematic review
- As a referee of systematic reviews
- Notifying the editorial base of any randomised controlled trials in kidney disease currently being undertaken or not published
- Carrying out hand-searching of journals particularly those that are not listed in Medline, and those published in languages other than English
- Sending abstract books of conference proceedings to the Editorial Base
- Offering technical or other support to members of the group
- Providing Consumer input

Of these, the most important task is the development of systematic reviews, and in the following sections we have provided some guidance. If you have any queries at all please contact the Editorial base.

How we can help you


The Renal Group's aim is to make the review process as painless as possible. For example you will have access to and help with:

- Access to the Renal Group's register of trials and we will provide a list of relevant trials
- Support with developing additional electronic and handsearching strategies
- Data collection checklists, which describes the inclusion criteria for studies, quality issues, and the collection of relevant data.
- Provide free workshops for all our authors
- Handbooks and software
- Phone and email support
- If required we will provide 1-2 weeks at the Editorial Base to help develop and complete reviews and protocols

The Review Process

The Cochrane Collaboration is an organisation committed to improving health care practice through the production of systematic reviews. If you think that you may be interested in undertaking a review for the Cochrane Renal Group, the first thing to do is to approach the Editorial Base in Sydney.

Enquiries about the Cochrane Renal Group's review process are most welcome and will not be viewed as a commitment to undertake a review.



A Cochrane review is submitted in four stages:

1. The title
2. The protocol
3. The review
4. Updating

From idea to title

Once you think you would like to undertake a Cochrane Renal Group review, please notify the Editorial Base of a topic area you are interested in. They will assist you in formulating your idea into a title that fits within the scope of the group and doesn't overlap with any existing titles. You will then be asked to complete a 'Title Registration Form'. The Cochrane Collaboration has a set format for titles so please refer to page 6 of this

booklet. When your title has been approved by the editorial office, you will be assigned a unique identifier. Your registered title is then circulated to all other Review Groups to ensure there is no crossover. If you discover that your idea for a review is already being addressed, you may be able to collaborate with them or develop an alternate idea.

An information booklet on writing a protocol will be forwarded to you on registration of your title. New booklets shall be forwarded at each stage of the review process.

After title registration

It is important that you read Chapter 2 of the Cochrane Handbook for Systematic Reviews of Interventions: Format of a Cochrane Review.

Chapter 2 indicates the methods and layout of a Cochrane review: reviews must conform to the specifications outlined in this section. This section will be forwarded to you on registration of your title. However reading it beforehand is of great benefit (you can read and/or download from www.cochrane-handbook.org).

The Cochrane Renal Group's aim is that all reviews undertaken for the group will be published in the Cochrane Database of Systematic Reviews (CDSR) within *The Cochrane Library*. *The Cochrane Library* is the main 'product' of The Cochrane Collaboration: it contains all the Cochrane reviews and protocols produced by the different Review Groups, in addition to a number of important, related databases.

Developing a protocol

Protocols expand on the title to describe the review.

As a rough guide, your protocol will need to address the following issues:

1. The specific purpose (question to be answered) of the review
2. The comparison groups (as the stated comparisons are central to each review, particular care should be taken with their development)
3. The sources and search methods used to find evidence (primary studies)
4. Explicit criteria for deciding which studies to include in the review
5. Avoidance of bias in the selection of articles
6. Reasons for excluding studies from the review
7. Appropriate criteria for assessing the quality of the studies
8. Appropriate methods (whether qualitative or quantitative) for combining the findings

When you have developed your protocol to your own satisfaction, it should be submitted to the Editorial Base. This means it will be entered into the Renal Group's referee process, en route to inclusion in *The Cochrane Library*.

Submission of the protocol is taken as your agreement to undertake a Renal Group systematic review. Therefore, you should only submit the protocol if this is your intention.

Headings of a Cochrane protocol

(Extract from Chapter 2 of the *Cochrane Handbook for Systematic Reviews of Interventions*)

Text:

BACKGROUND
OBJECTIVES
CRITERIA FOR SELECTING STUDIES FOR THIS REVIEW
 TYPES OF STUDIES
 TYPES OF PARTICIPANTS
 TYPES OF INTERVENTION(S)
 TYPES OF OUTCOME MEASURES
SEARCH STRATEGY FOR IDENTIFICATION OF STUDIES
DATA COLLECTION AND ANALYSIS
ACKNOWLEDGEMENTS

References:

ADDITIONAL REFERENCES

Developing your review

Your protocol describes your review methods and it will guide you in developing your review. The editorial process for reviews is similar to that for a protocol.

When you have completed your review to your own satisfaction it should be submitted 'formally' to the Editorial Base. This means that it will again be entered into the Renal Group referee process. The same referees of the protocol also referee the review, with the addition of our Statistical Advisor. The comments from all referees will be provided to you by the Managing Editor. Following any necessary revisions and approval by the Editorial Team, the completed review is submitted to *The Cochrane Library* for publication. Once your review is published you are entitled to a free subscription to *The Cochrane Library* and you will receive a copy four times a year.

Updating your review

As the aim of The Cochrane Collaboration is to provide up to date information, you will be expected to update your review as required. This may involve inclusion of new trials relevant to your title or responding to comments and criticisms. The Trials Search Coordinator will regularly search the Trials Register for you and notify you when new trials are published.

In addition to updating your review, you may be contacted concerning issues relating to your review. You are expected to reply to these

comments and criticisms within an appropriate time frame, and they will appear in the next issue of *The Cochrane Library*.

How long should a review take?

A Cochrane review is never 'finished'. There are, however, steps along the way that we can roughly estimate.

Title to protocol	approx. 3 months
Protocol to review	approx. 6-12 months
Updates	at least every 2 years (regular literature searches are made by the Trials Search Coordinator for you)

Cochrane title format

The basic title format is

[intervention] FOR [health problem]

eg Antibiotics for acute bronchitis

Where two active interventions have been compared, the structure is:

[Intervention A] VERSUS [intervention B] FOR [health problem]

eg Immediate versus delayed treatment for cervical intraepithelial neoplasia

Where the type of people studied or the location of the intervention is mentioned explicitly, the format is:

[Intervention] FOR [health problem] IN [participant group/location]

eg Inhaled nitric oxide for respiratory failure in preterm infants

Sometimes it might be necessary to specify that the intervention is for preventing, treating, or preventing and treating the problem(s) concerned.

[Intervention] FOR [preventing and/or treating] [health problem] IN [participant group/location]

eg Pool fencing for preventing drowning in children
Amodiaquine for treating malaria

For many prophylactic interventions there is often no specified 'health problem'

[Intervention] IN or FOR [participant group/location].

eg Restricted versus liberal water intake in preterm infants
Home-based social support for socially disadvantaged mothers

Cochrane Renal Group topic areas and scope

The Cochrane Renal Group's scope covers the following major areas of kidney disease.

- **Acute kidney injury**
- **Chronic kidney disease**
- **End-stage kidney disease**
- **Kidney transplantation**
- **Drugs and the kidney**
- **Renovascular hypertension**
- **Urinary tract infections**
- **Nephrolithiasis**

Published reviews, protocols and registered titles

To date we have 91 reviews and 76 protocols published in *The Cochrane Library* (www.thecochranelibrary.com) (Issue 12, 2010 release date December 2010). In addition we have 61 titles registered with our group. To see the most up-to-date list please go to <http://www.cochrane.org/reviews/en/topics/89.html>.

Published reviews

1. [Aldosterone antagonists for preventing the progression of chronic kidney disease](#)
Sankar D Navaneethan, Sagar U Nigwekar, Ashwini R Sehgal, Giovanni FM Strippoli
2. [Altered dietary salt intake for preventing and treating diabetic kidney disease](#)
Rebecca J Suckling, Feng J He, Graham A MacGregor
3. [Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease](#)
Giovanni FM Strippoli, Carmen Bonifati, Maria E Craig, Sankar D Navaneethan, Jonathan C Craig
4. [Antibiotic duration for treating uncomplicated, symptomatic lower urinary tract infections in elderly women](#)
Monika Lutters, Nicole B Vogt-Ferrier
5. [Antibiotics for acute pyelonephritis in children](#)
Elisabeth M Hodson, Narelle S Willis, Jonathan C Craig
6. [Antibiotics for preventing recurrent urinary tract infection in non-pregnant women](#)
Xavier Albert, Isabel Huertas, Inmaculado Pereiro, José Sanfélix, Victoria Gosalbes, Carla Perrotta
7. [Antifungal agents for preventing fungal infections in solid organ transplant recipients](#)
Elliott Geoffrey Playford, Angela C Webster, Jonathan C Craig, Tania C Sorrell
8. [Antihypertensive agents for preventing diabetic kidney disease](#)
Giovanni FM Strippoli, Maria E Craig, Jonathan C Craig, Jicheng Lv, Vlado Perkovic
9. [Antihypertensive treatment for kidney transplant recipients](#)
Nicholas B Cross, Angela C Webster, Philip Masson, Philip J O'Connell, Jonathan C Craig
10. [Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients](#)
Giovanni FM Strippoli, Allison Tong, David W Johnson, Francesco Paolo Schena, Jonathan C Craig
11. [Antimicrobial agents for treating uncomplicated urinary tract infection in women](#)
Anca Zalmanovici Trestioreanu, Hefziba Green, Mical Paul, John Yaphe, Leonard Leibovici
12. [Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients](#)
Elisabeth M Hodson, Jonathan C Craig, Giovanni FM Strippoli, Angela C Webster
13. [Atrial natriuretic peptide for preventing and treating acute kidney injury](#)
Sagar U Nigwekar, Sankar D Navaneethan, Chirag R Parikh, John K Hix
14. [Bicarbonate versus lactate solutions for acute peritoneal dialysis](#)
Zheng Gang Bai, KeHu Yang, Jinhui Tian, Bin Ma, Yali Liu, Lei Jiang, Jiying Tan, Tian Xi Liu, Iris Chi
15. [Biocompatible hemodialysis membranes for acute renal failure](#)
Alvaro Alonso, Joseph Lau, Bertrand L Jaber

16. Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients
Giovanni FM Strippoli, Allison Tong, Suetonia C Palmer, Grahame J Elder, Jonathan C Craig
17. Calcium channel blockers for preventing acute tubular necrosis in kidney transplant recipients
Ilona R Shilliday, Mohammed Sherif
18. Catheter type, placement and insertion techniques for preventing peritonitis in peritoneal dialysis patients
Giovanni FM Strippoli, Allison Tong, David W Johnson, Francesco Paolo Schena, Jonathan C Craig
19. Cellulose, modified cellulose and synthetic membranes in the haemodialysis of patients with end-stage renal disease
Alison M MacLeod, Marion K Campbell, June D Cody, Conal Daly, Adrian Grant, Izhar Khan, Kannaiyan S Rabindranath, Luke Vale, Sheila A Wallace
20. Chinese herbal medicine Huangqi type formulations for nephrotic syndrome
Wei Yuan, Juan Wang, Taixiang Wu
21. Continuous ambulatory peritoneal dialysis (CAPD) versus hospital or home haemodialysis for end-stage renal disease in adults
Luke Vale, June D Cody, Sheila A Wallace, Conal Daly, Marion K Campbell, Adrian Grant, Izhar Khan, Alison M MacLeod
22. Continuous ambulatory peritoneal dialysis versus automated peritoneal dialysis for end-stage renal disease
Kannaiyan S Rabindranath, James Adams, Tariq Z Ali, Alison M MacLeod, Luke Vale, June D Cody, Sheila A Wallace, Conal Daly
23. Correction of chronic metabolic acidosis for chronic kidney disease patients
Paul J Roderick, Narelle S Willis, Sara Blakeley, Chris Jones, Charles Tomson
24. Corticosteroid therapy for nephrotic syndrome in children
Elisabeth M Hodson, Narelle S Willis, Jonathan C Craig
25. Cranberries for preventing urinary tract infections
Ruth G Jepson, Jonathan C Craig
26. Cranberries for treating urinary tract infections
Ruth G Jepson, Lara Mihaljevic, Jonathan C Craig
27. Cytomegalovirus prophylaxis with antiviral agents for solid organ transplantation
Cecile Couchoud-Heyer
28. Double bag or Y-set versus standard transfer systems for continuous ambulatory peritoneal dialysis in end-stage renal disease
Conal Daly, Marion K Campbell, June D Cody, Adrian Grant, Izhar Khan, Paul Lawrence, Alison M MacLeod, Kannaiyan S Rabindranath, Luke Vale, Sheila A Wallace
29. Duration of antibacterial treatment for uncomplicated urinary tract infection in women
Gai Milo, Eugene Katchman, Mical Paul, Thierry Christiaens, Anders Baerheim, Leonard Leibovici
30. Effects of nonsteroidal anti-inflammatory drugs on postoperative renal function in adults with normal renal function
Anna Lee, Michael G Cooper, Jonathan C Craig, John F Knight, John P Keneally
31. Emergency interventions for hyperkalaemia
Brian A Mahoney, Willard AD Smith, Dorothy Lo, Keith Tsoi, Marcello Tonelli, Catherine Clase
32. Extra-corporeal shock wave lithotripsy (ESWL) versus ureteroscopic management for ureteric calculi
Ghulam Nabi, Paul Downey, Francis X Keeley, Graham M Watson, Samuel McClinton
33. Extracorporeal shock wave lithotripsy (ESWL) versus percutaneous nephrolithotomy (PCNL) or retrograde intrarenal surgery (RIRS) for kidney stones
Attasit Srisubat, Somkiat Potisat, Bannakij Lojanapiwat, Vasun Setthawong, Malinee Laopaiboon
34. Fish oil for kidney transplant recipients
Andy KH Lim, Karen J Manley, Matthew A Roberts, Margaret B Fraenkel
35. Fluids and diuretics for acute ureteric colic
Andrew S Worster, Crispen G Richards
36. Frequency of administration of recombinant human erythropoietin for anaemia of end-stage renal disease in dialysis patients
June D Cody, Conal Daly, Marion K Campbell, Cam Donaldson, Izhar Khan, Luke Vale, Sheila A Wallace, Alison M MacLeod
37. Growth hormone for children with chronic kidney disease
Dushyanthi Vimalachandra, Elisabeth M Hodson, Narelle S Willis, Jonathan C Craig, Christopher T Cowell, John

F Knight

38. Haemodiafiltration, haemofiltration and haemodialysis for end-stage kidney disease
Kannaiyan S Rabindranath, Giovanni FM Strippoli, Conal Daly, Paul J Roderick, Sheila A Wallace, Alison M MacLeod
39. Haemoglobin and haematocrit targets for the anaemia of chronic kidney disease
Giovanni FM Strippoli, Sankar D Navaneethan, Jonathan C Craig, Suetonia C Palmer
40. Heparin and related substances for preventing diabetic kidney disease
Jun Li, Hong Mei Wu, Ling Zhang, Bin Zhu, Bi Rong Dong
41. HMG CoA reductase inhibitors (statins) for dialysis patients
Sankar D Navaneethan, Sagar U Nigwekar, Vlado Perkovic, David W Johnson, Jonathan C Craig, Giovanni FM Strippoli
42. HMG CoA reductase inhibitors (statins) for kidney transplant recipients
Sankar D Navaneethan, Vlado Perkovic, David W Johnson, Sagar U Nigwekar, Jonathan C Craig, Giovanni FM Strippoli
43. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis
Sankar D Navaneethan, Francesca Pansini, Vlado Perkovic, Carlo Manno, Fabio Pellegrini, David W Johnson, Jonathan C Craig, Giovanni FM Strippoli
44. Human albumin for intradialytic hypotension in haemodialysis patients
Patricia M Fortin, Ken Bassett, Vijaya M Musini
45. Hydroxyethyl starch (HES) versus other fluid therapies: effects on kidney function
Allison B Dart, Thomas C Mutter, Chelsea A Ruth, Shayne P Taback
46. Immunoglobulins, vaccines or interferon for preventing cytomegalovirus disease in solid organ transplant recipients
Elisabeth M Hodson, Cheryl A Jones, Giovanni FM Strippoli, Angela C Webster, Jonathan C Craig
47. Immunosuppressive agents for treating IgA nephropathy
Ruchdi Barakat, Donald A Molony, Joshua A Samuels
48. Immunosuppressive treatment for focal segmental glomerulosclerosis in adults
Norbert Braun, Frank Schmutzler, Catalina Lange, Annalisa Perna, Giuseppe Remuzzi, Narelle S Willis
49. Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome
Arrigo Schieppati, Annalisa Perna, Javier Zamora, Giovanni A Giuliano, Norbert Braun, Giuseppe Remuzzi
50. Interleukin 2 receptor antagonists for kidney transplant recipients
Angela C Webster, Lorenn P Ruster, Richard McGee, Sandra L Matheson, Gail Y Higgins, Narelle S Willis, Jeremy R Chapman, Jonathan C Craig
51. Intermittent versus continuous renal replacement therapy for acute renal failure in adults
Kannaiyan S Rabindranath, James Adams, Alison M MacLeod, Norman Muirhead
52. Interventions for bone disease in children with chronic kidney disease
Denis F Geary, Elisabeth M Hodson, Jonathan C Craig
53. Interventions for haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura
Mini Michael, Elizabeth J Elliott, Greta F Ridley, Elisabeth M Hodson, Jonathan C Craig
54. Interventions for HIV-associated nephropathy
Ismail Yahaya, Olalekan A Uthman, Muhammed Mubashir B Uthman
55. Interventions for idiopathic steroid-resistant nephrotic syndrome in children
Elisabeth M Hodson, Narelle S Willis, Jonathan C Craig
56. Interventions for minimal change disease in adults with nephrotic syndrome
Suetonia C Palmer, Kushma Nand, Giovanni FM Strippoli
57. Interventions for preventing and treating kidney disease in Henoch-Schönlein Purpura (HSP)
Wattana Chartapisak, Sauwalak Opastirakul, Elisabeth M Hodson, Narelle S Willis, Jonathan C Craig
58. Interventions for preventing bone disease in kidney transplant recipients
Suetonia C Palmer, David O McGregor, Giovanni FM Strippoli
59. Interventions for preventing infection in nephrotic syndrome
Hong Mei Wu, Jin-Ling Tang, Zhao Hui Sha, Youping Li, I Cao

60. Interventions for preventing infectious complications in haemodialysis patients with central venous catheters
Margaret McCann, Zena EH Moore
61. Interventions for primary vesicoureteric reflux
Elisabeth M Hodson, Danielle M Wheeler, Grahame H Smith, Jonathan C Craig, Dushyanthi Vimalachandra
62. Interventions for renal vasculitis in adults
Giles Walters, Narelle S Willis, Jonathan C Craig
63. Interventions for treating sexual dysfunction in patients with chronic kidney disease
Mariacristina Vecchio, Sankar D Navaneethan, David W Johnson, Giuseppe Lucisano, Giusi Graziano, Valeria Saglimbene, Marinella Ruospo, Marialuisa Querques, Emmanuele A Jannini, Giovanni FM Strippoli
64. Long-term antibiotics for preventing recurrent urinary tract infection in children
Gabrielle Williams, Lei Wei, Anna Lee, Jonathan C Craig
65. Low protein diets for chronic kidney disease in non diabetic adults
Denis Fouque, Maurice Laville
66. Methenamine hippurate for preventing urinary tract infections
Bon San B Lee, Judy M Simpson, Jonathan C Craig, Tushar Bhuta
April 2010
67. Modes of administration of antibiotics for symptomatic severe urinary tract infections
Annette Pohl
68. Non-corticosteroid treatment for nephrotic syndrome in children
Elisabeth M Hodson, Narelle S Willis, Jonathan C Craig
69. Nonsteroidal anti-inflammatory drugs (NSAIDS) versus opioids for acute renal colic
Anna Holdgate, Tamara Pollock
70. Nutritional support for acute kidney injury
Yi Li, Xi Tang, Juqian Zhang, Taixiang Wu
71. Oestrogens for preventing recurrent urinary tract infection in postmenopausal women
Carla Perrotta, Mireya Aznar, Raul Mejia, Xavier Albert, Cheen Werne Ng
72. Pharmacological interventions for preventing complications in idiopathic hypercalciuria
Joaquin Escribano, Albert Balaguer, Filomena Pagone, Albert Feliu, Marta Roqué i Figuls
73. Physical measures for treating depression in dialysis patients
Kannaiyan S Rabindranath, Janet Butler, Paul J Roderick, Sheila A Wallace, Conal Daly, Alison M MacLeod
74. Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients
Angela C Webster, Tanya Pankhurst, Fiona Rinaldi, Jeremy R Chapman, Jonathan C Craig
75. Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients
Giovanni FM Strippoli, Elisabeth M Hodson, Cheryl A Jones, Jonathan C Craig
76. Prostaglandin E1 for preventing the progression of diabetic kidney disease
Han Wang, Jue Lin Deng, Jirong Yue, Jun Li, Yan Bin Hou
77. Protein restriction for children with chronic kidney disease
Swasti Chaturvedi, Colin Jones
78. Psychosocial interventions for depression in dialysis patients
Kannaiyan S Rabindranath, Conal Daly, Janet Butler, Paul J Roderick, Sheila A Wallace, Alison M MacLeod
79. Quinolones for uncomplicated acute cystitis in women
Vladimir V Rafalsky, Irina V Andreeva, Elena L Rjabkova
80. Recombinant human erythropoietin for chronic renal failure anaemia in pre-dialysis patients
June D Cody, Conal Daly, Marion K Campbell, Izhar Khan, Kannaiyan S Rabindranath, Luke Vale, Sheila A Wallace, Alison M MacLeod, Adrian Grant, Susan Pennington
81. Routine intraoperative ureteric stenting for kidney transplant recipients
Colin H Wilson, Aftab B Bhatti, David A Rix, Derek M Manas
82. Short versus standard duration oral antibiotic therapy for acute urinary tract infection in children
Mini Michael, Elisabeth M Hodson, Jonathan C Craig, Sarah Martin, Virginia A Moyer

83. Steroid avoidance or withdrawal for kidney transplant recipients
Julio Pascual, Javier Zamora, Cristina Galeano, Ana Royuela, Carlos Quereda
84. Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients
Angela C Webster, Rod RS Taylor, Jeremy R Chapman, Jonathan C Craig
85. Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients
Angela C Webster, Vincent WS Lee, Jeremy R Chapman, Jonathan C Craig
86. Teicoplanin versus vancomycin for proven or suspected infection
Alexandre B Cavalcanti, Anderson R Goncalves, Claudia S Almeida, Diogo DG Bugano, Eliezer Silva
87. Treatment for lupus nephritis
Robert S Flanc, Matthew A Roberts, Giovanni FM Strippoli, Steven J Chadban, Peter G Kerr, Robert C Atkins
88. Treatment for peritoneal dialysis-associated peritonitis
Kathryn J Wiggins, Jonathan C Craig, David W Johnson, Giovanni FM Strippoli
89. Vitamin D compounds for people with chronic kidney disease not requiring dialysis
Suetonia C Palmer, David O McGregor, Jonathan C Craig, Grahame Elder, Petra Macaskill, Giovanni FM Strippoli
90. Vitamin D compounds for people with chronic kidney disease requiring dialysis
Suetonia C Palmer, David O McGregor, Jonathan C Craig, Grahame Elder, Petra Macaskill, Giovanni FM Strippoli
91. Water for preventing urinary calculi
Zhang Ke, Qiang Wei

Published protocols

1. Advanced glycation end product (AGE) inhibitors for preventing the progression of diabetic kidney disease
Andre Luis A Lemos, Álvaro N Atallah, Elisa M S Higa, Hernani P Lemos Jr
2. Alpha-blockers as medical expulsive therapy for ureteral stones
Yefang Zhu, Maroeska M Rovers, Diederick Duijvesz, M T W Tycho Lock
3. Amphotericin B deoxycholate versus liposomal amphotericin B: effects on kidney function
Jason M Cota, James N Barnes, Bradi Frei, Christopher R Frei, Nathan P Wiederhold
4. Androgens for the anaemia of chronic kidney disease in adults
Xi Tang, Rui Gu, Xi Sheng Xie, Taixiang Wu
5. Angiotensin converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1-3) non-diabetic chronic kidney disease
Rachel C Blackburn, Claire L Parke, Pawana Sharma, Keith McCullough, Corri Black
6. Antibiotic prophylaxis for preventing post solid organ transplant tuberculosis
Bappa Adamu, Aliyu Abdu, Abdullahi A Abba, Musa M Borodo, Imad M Tleyieh
7. Antibiotics for preventing urinary tract infections in kidney transplant recipients
Abdulmalik M Alkatheri, Ali Hajeer, Hanan Al Kadri, Majed Al-Jeraisy, Abullah Alsayyari
8. Antibiotics for treating uncomplicated urinary tract infection in children
Anita Fitzgerald, Chia-Wen Lee, Rintaro Mori
9. Antibody immunosuppression for pancreas and kidney/pancreas transplant recipients
Kathy Kable, Peter Barclay, Angela C Webster, Jeremy R Chapman, Jonathan C Craig
10. Antihypertensive agents for dialysis patients
David Tellez, Cesar Loza Munarriz
11. Antihypertensive agents for preventing the progression of diabetic kidney disease
Giovanni FM Strippoli, Maria E Craig, Francesco Paolo Schena, Jonathan C Craig
12. Antioxidants for chronic kidney disease
Vlado Perkovic, Vinod Venkataraman, Bruce Cooper, Sophia Zoungas, Angela C Webster

13. Antiplatelet agents for chronic kidney disease
Mona Razavian, Lucia Di Micco, Suetonia C Palmer, Jonathan C Craig, Vlado Perkovic, Sophia Zoungas, Angela C Webster, Meg J Jardine, Giovanni FM Strippoli
14. Bicarbonate versus lactate solutions for acute haemodialysis
Jin Hui Tian, Bin Ma, Ya Li Liu, Ji Ying Tan, Ke Hu Yang, Tian Xi Liu
15. Biocompatible dialysis fluids for peritoneal dialysis
Kathryn J Wiggins, Jonathan C Craig, David W Johnson, Giovanni FM Strippoli
16. Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients
Krishna M Karpe, Girish S Talaulikar, Giles Walters
17. Calcium dialysate concentration for peritoneal dialysis
Tian Kang Guo, Xiang Yong Hao, Ke Hu Yang, Bin Ma, Hong Ling Li, Jin Hui Tian, Ya Li Liu, Lei Jiang, Zheng Gang Bai
18. Cardiac testing for coronary artery disease in potential kidney transplant recipients
Louis W Wang, Magid A Fahim, Andrew Hayen, Ruth L Mitchell, Laura Baines, Stephen Lord, Jonathan C Craig, Angela C Webster
19. Chinese medicinal herbs for diabetic kidney disease
Jianping Liu, Yanke Ai, Xia Wan, Hong Wei Zhang, Yutong Fei
20. Chinese medicinal herbs for urinary calculi
Liang Du, Jin Huang, Xuemei Liu
21. Continuous renal replacement modalities for acute kidney failure in critically ill patients
Alicia I Fayad, Daniel G Buamscha, Agustín Ciapponi, Alvaro Rodriguez Palacios
22. Continuous renal replacement therapy (CRRT) for rhabdomyolysis
Xiaoxi Zeng, Ping Fu
23. Cordyceps sinensis (a Chinese medicinal herb) for treating chronic kidney disease
Hong Wei Zhang, Yi Fong Ho, Zhi Xiu Lin, Yuk Stewart Tung, Tze Hoi Kwan, Chun Keung Mok, Connie Leung, Lai Sum Chan
24. Dietary interventions for preventing complications in idiopathic hypercalciuria
Albert Balaguer, Joaquin Escribano, Albert Feliu, Marta Roqué i Figuls
25. Diuretics for treating oedema in nephrotic syndrome
Pavel Geier, Jan Strojil, Katerina Kutrova, Jarmila Potomkova, Janusz Feber
26. Donor organ preservation techniques for kidney transplantation
Colin H Wilson, John F Asher, David Talbot
27. Early referral to specialist nephrology services for preventing the progression to end-stage kidney disease
Neil A Smart, Thomas Titus, Liz Dooley
28. Education programmes for people with diabetic kidney disease
Hong Mei Wu, Feng Wang, Chang Quan Huang, Ming Yang, Bi Rong Dong, Guan Jian Liu
29. Endoscopic treatment with or without stenting for the management of ureteric calculi
Kesavapillai Subramonian, Ken Anson
30. Exercise training for adults with chronic kidney disease
Susanne Heiwe, Stefan H Jacobson
31. Fluid and diuretic therapy for preventing cisplatin-induced nephrotoxicity
Florian Buchkremer
32. FTY720 immunosuppression for kidney transplant recipients
Ji Ying Tan, Yu Min Wu, Ke Hu Yang, Bin Ma, Hong Li Pang, Jin Hui Tian, Lei Jiang, Zheng Gang Bai, Youping Li
33. Growth factors for chronic kidney disease in adults
Ghazwan Altabbaa, Brenda R Hemmelgarn, Vinay Deved

34. Heparin and related substances for delaying the progression of diabetic kidney disease
Xi Sheng Xie, Yang Man, Junming Fan, Yujiao Wang, Taixiang Wu
35. High-flux versus low-flux haemodialysis membranes for end-stage renal disease
Kannaiyan S Rabindranath, Giovanni FM Strippoli, Conal Daly, Paul J Roderick, Sheila A Wallace, Alison M MacLeod
36. Insulin-sensitising therapies for preventing the progression of diabetic kidney disease
Huai-Sheng Chen, Jianping Liu, Wei Wang
37. Intensive versus standard haemodialysis water treatment for preventing low grade mineral intoxication in chronic haemodialysed patients
Marcelo S Chaves, Agustín Ciapponi, Vanda Jorgetti
38. Interventions for covert bacteriuria in children
Anita Fitzgerald, Rintaro Mori, Monica Lakhanpaul
39. Interventions for dialysis patients with hepatitis C virus (HCV) infection
Ravindra A Prabhu, Naresh K Goyal, N S Nair, Ganesh Pai, Tarun Wadhwa
40. Interventions for erythropoietin-resistant anaemia in dialysis patients
Sunil V Badve, Elaine Beller, Alan Cass, Daniel P Francis, Carmel Hawley, Iain C Macdougall, Vlado Perkovic, David W Johnson
41. Interventions for lowering plasma homocysteine levels in dialysis patients
Sagar U Nigwekar, Alan Cass, Martin P Gallagher, Meg J Jardine, Amy Kang, Satyarth Kulshrestha, Sankar D Navaneethan, Vlado Perkovic, Giovanni FM Strippoli, Sophia Zoungas
42. Interventions for lowering plasma homocysteine levels in kidney transplant recipients
Amy Kang, Sagar U Nigwekar, Vlado Perkovic, Satyarth Kulshrestha, Sophia Zoungas, Sankar D Navaneethan, Alan Cass, Martin P Gallagher, Toshiharu Ninomiya, Giovanni FM Strippoli, Meg J Jardine
43. Interventions for lowering plasma homocysteine levels in predialysis patients
Kingsley N Urakpo, Pirzada M Anwer
44. Interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy
Suzi Robertson-Malt, Gillian J Ingram, Craig Lockwood
45. Interventions for preventing thrombosis in adults and children with nephrotic syndrome
Satyarth Kulshrestha, Marvin Grieff, Sankar D Navaneethan
46. Isolation as a strategy for controlling the transmission of hepatitis C virus (HCV) infection in haemodialysis units
Jessica I Bravo, Cesar Loza Munarriz
47. Laparoscopic versus open nephrectomy for live kidney donors
Aliu Sanni, David A Rix, Naeem Soomro, Colin H Wilson
48. Lipid-lowering agents for nephrotic syndrome
Junming Fan, Zi Li, Taixiang Wu, Haiyan Chen
49. Low molecular weight heparin (LMWH) versus unfractionated heparin (UFH) for haemodialysis anticoagulation
Xi Sheng Xie, Kun Yang, Chuan Zuo, Junming Fan
50. Mycophenolic acid versus azathioprine as primary immunosuppression for kidney transplant recipients
Martin Wagner, Ethan M Balk, Angela C Webster, Gowri Raman, Thomas A Trikalinos, Christopher H Schmid, Katrin Uhlig
51. Non-immunosuppressive treatment for IgA nephropathy
Joshua A Samuels, Giovanni FM Strippoli, Jonathan C Craig, Francesco Paolo Schena, Donald A Molony
52. Nonsteroidal anti-inflammatory drugs (NSAIDs) and non-opioids for acute renal colic
Kourosh Afshar, Andrew E MacNeily, Andrew J Marks, Siavash Jafari
53. Oral adsorbents for preventing or delaying the progression of chronic kidney disease
Hong Mei Wu, Hong Juan Sun, Feng Wang, Ming Yang, Bi Rong Dong, Guan J Liu
54. Parenteral versus oral iron therapy for adults and children with chronic kidney disease
Jumana Albaramki, Elisabeth M Hodson, Jonathan C Craig

55. Pentoxifylline for diabetic kidney disease
Hong Mei Wu, Qi Yuan Yuan, Rong Le Zhou, Jun Li, Guan Jian Liu
56. Percussion, diuresis and inversion therapy for the passage of lower pole kidney stones after shock wave lithotripsy
Liang Ren Liu, Qi Jun Li, Qiang Wei, Zhen Hua Liu, Yong Xu
57. Pharmacological interventions for preventing contrast-induced nephropathy
Wiktoria Lesniak, Malgorzata Bala, Bozena Dubiel, Michael H Duong, Agnieszka Pardala, Piotr Gajewski
58. Phosphate binders for preventing and treating bone disease in chronic kidney disease patients
Sankar D Navaneethan, Suetonia C Palmer, Mariacristina Vecchio, Jonathan C Craig, Grahame Elder, Giovanni FM Strippoli
59. Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients
Angela C Webster, Jeremy R Chapman, Jonathan C Craig, John D Mahan, Lois C Orton, Tanya Pankhurst, Nick Webb
60. Preoperative vascular access evaluation for haemodialysis patients
Charmaine E Lok, Louise Moist
61. Probiotics for preventing urinary tract infections in adults and children
Erin M Schwenger, Aaron M Tejani, Peter S Loewen
62. Radix Astragali (a Chinese medicinal herb) for treating chronic kidney disease
Hong Wei Zhang, Yi Fong Ho, Zhi Xiu Lin, Yuk Stewart Tung, Tze Hoi Kwan, Chun Keung Mok, Connie Leung, Lai Sum Chan
63. Recombinant human insulin-like growth factor I for acute kidney injury
Y Jin, Jing Rong Song, Ke Hu Yang, Jin Hui Tian, Ya Li Liu, Bin Ma, Ji Ying Tan, Tian Xi Liu
64. Renal replacement therapy for preventing contrast-induced nephropathy
Wiktoria Lesniak, Malgorzata Bala
65. Rheum officinale (a Chinese medicinal herb) for chronic kidney disease
Han Wang, Jirong Yue, Jun Li, Yan Bin Hou, Jue Lin Deng
66. Single dose antibiotics for treating uncomplicated urinary tract infection in non-pregnant women
Jun Li Zhao, Jian Qin Wang, Lin Zhao, Zhi Ping Wang, Jing Yu Wang, Jun Zhang
67. Sodium ferulate for preventing the progression of diabetic kidney disease
Hong Yin, Ke Hu Yang, Xiang Yan, Bin Ma, Jin Hui Tian, Shao Liang Sun, Jun Li, Ruifeng Liu
68. Steroid avoidance or withdrawal for pancreas and kidney transplant recipients
Julio Pascual, Cristina Galeano, Carlos Quereda, Ana Royuela, Javier Zamora
69. Tacrolimus for simultaneous kidney-pancreas transplant recipients
Shu Shi Huang, Na Zhao, Shengfu Li, Dan Long, Xin Duan, Youping Li
70. Tacrolimus versus cyclosporin as primary immunosuppression for lung transplant recipients
Luit Penninga, Elisabeth I Penninga, Christian H Møller, Daniel A Steinbrüchel, Christian Gluud
71. Therapeutic interventions for idiopathic membranoproliferative glomerulonephritis
Zi Li, Ping Fu, Taixiang Wu, Li He, Jing Li
72. Thyroxine for acute kidney injury
Sagar U Nigwekar, Sankar D Navaneethan, Giovanni FM Strippoli
73. Tidal peritoneal dialysis for acute renal failure
Lei Jiang, Ke Hu Yang, Deng Hai Mi, Ya Li Liu, Jin Hui Tian, Bin Ma, Zheng Gang Bai, Tian Xi Liu, Ji Ying Tan
74. Tripterygium wilfordii Hook F (a traditional Chinese medicine) for primary nephrotic syndrome
Yi-Zhi Chen, Xue-Zhi Zhao, Qing Yuan
75. Ultrasound use for the placement of haemodialysis catheters
Emma C Vaux, Ranjit Shail, Kannaiyan S Rabindranath
76. Upper limb exercise for haemodialysis fistula surgery
Susanne Heiwe, Pia Johansson, Yvonne Wengstrom, Stefan H Jacobson

Registered titles

1. Accuracy of NGAL for acute renal injury in kidney transplantation (title)
2. Acupuncture for chronic kidney disease (title)
3. Acupuncture for renal colic (title)
4. Adjunctive medical expulsive therapy for renal and ureteral stone fragments following shock wave lithotripsy (title)
5. Angiotensin converting enzyme inhibitors and angiotensin II receptor blockers for preserving residual kidney function in peritoneal dialysis patients (title)
6. Antibiotic lock therapy for preventing dialysis catheter related infections in hemodialysis patients (title)
7. Antibiotic prophylaxis for transurethral endo-urological procedures (title)
8. Antibiotics for asymptomatic bacteriuria (title)
9. Antibiotics for preventing recurrent urinary tract infection in men (title)
10. Antibody induction therapy for lung transplant recipients (title)
11. Anticoagulants for preventing thrombosis of central venous haemodialysis catheters in end-stage kidney disease (title)
12. Antihypertensive agents for children with chronic kidney disease (title)
13. Aspiration and sclerotherapy versus hydrocelectomy for treating hydroceles (title)
14. Calcium channel blockers as medical expulsive therapy for ureteric stones (title)
15. Citrate salts for preventing and treating kidney stones (title)
16. Clinical and physical signs for identifying dehydration in older people (title)
17. Continuous erythropoiesis receptor activator (CERA) for the anaemia of chronic kidney disease (title)
18. Conventional dissection versus plastic device circumcision for treating phimosis in pediatric patients (title)
19. Cordyceps sinensis (a traditional Chinese medicine) for kidney transplant recipients (title)
20. Cyclosporin target values in the immediate post-operative period for kidney transplant recipients (title)
21. Darbepoetin for the anaemia of chronic kidney disease (title)
22. Dialysate temperature for haemodialysis (title)
23. Dialyser reuse for people on haemodialysis (title)
24. Dopamine for acute kidney injury (title)
25. Dopamine for preventing early graft dysfunction in kidney transplant recipients (title)
26. Educational interventions for metabolic bone disease in patients with chronic kidney disease (title)
27. Glucose lowering therapies for chronic kidney disease and kidney transplantation (title)
28. Glucose targets for preventing diabetic kidney disease and its progression (title)
29. Haemodialysis duration and frequency for end-stage kidney disease (title)
30. HMG CoA reductase inhibitors (statins) for preventing acute kidney injury after surgical procedures requiring cardiac bypass (title)
31. Human albumin infusion for nephrotic syndrome (title)
32. Interventions for chronic kidney disease-associated restless legs syndrome (title)
33. Interventions for implementing evidence-based medicine in renal clinical practice (title)
34. Interventions for leg cramps in people on dialysis (title)
35. Interventions for nephropathic cystinosis (title)
36. Interventions for pelvi-ureteric junction (PUJ) obstruction in children (title)
37. Interventions for preventing intradialytic hypotension in haemodialysis patients (title)
38. Interventions for pruritus in chronic kidney disease (title)
39. Loop diuretics for acute kidney injury in adults and children (title)

40. Loop diuretics for patients receiving blood transfusions (title)
41. Maintenance calcineurin inhibitor levels for kidney transplant recipients (title)
42. Nutritional supplements for adults with end-stage kidney disease on renal replacement therapy (title)
43. Parathyroidectomy for chronic kidney disease-mineral and bone disorder (CKD-MBD) (title)
44. Pentoxifylline for chronic kidney disease (title)
45. Percutaneous angioplasty or stenting for stenosed but functioning haemodialysis access fistulae and grafts (title)
46. Pidotimod for preventing recurrent urinary tract infection (title)
47. Probiotics for preventing urinary tract infection in people with neuropathic bladder (title)
48. Probiotics for treating multi-resistant organism (MRO) colonisation/infection (title)
49. Procalcitonin, C-reactive protein, and erythrocyte sedimentation rate for diagnosing acute pyelonephritis in children with UTI (title)
50. Single dose antibiotics for treating urinary tract infection in children (title)
51. Single versus simultaneous-double paediatric donor organs for adult kidney transplant recipients (title)
52. Sodium bicarbonate supplements for acute kidney injury (title)
53. Supine versus prone positioning for percutaneous nephrolithotripsy (PNL) (title)
54. Support interventions for caregivers of patients with chronic kidney disease (title)
55. Target of rapamycin inhibitors (TORi) as maintenance immunosuppression for kidney transplant recipients (title)
56. Topical corticosteroids for treating phimosis in boys (title)
57. Treatment for BK virus nephropathy in kidney transplant recipients (title)
58. Tubeless versus standard percutaneous nephrolithotomy for treating kidney stones (title)
59. Uric acid lowering therapies for chronic kidney disease (title)
60. Vascular access surveillance for patients on haemodialysis (title)
61. Vascular access type for people on chronic haemodialysis (title)

Contact Details

Cochrane Renal Group
Centre for Kidney Research
Locked Bag 4001
Westmead, NSW 2145
Australia
Tel: +61 (0)2 9845 1478
Fax: +61 (0)2 9845 1491
Email: crg@chw.edu.au
Web: www.cochrane-renal.org

Upcoming meetings and workshops

For an up-to-date list please contact our office or go to

<http://www.cochrane.org/training>



FAX-BACK FORM

I am interested in undertaking a Cochrane systematic review on the following topic

Provisional title (***Intervention for health condition in population***)

.....
.....
.....

(Please give a brief description of)

Participants:
.....
.....

Interventions:
.....
.....

Outcomes:
.....
.....

Contact details of primary author:

Name:

Email:

Is there any potential conflict of interest? (e.g. Involved in clinical trials in the field or funding from the pharmaceutical industry etc. if none, please write 'none known')

.....
.....

Please send me a copy of the Cochrane Renal Group's title registration form.

Please fax to +61 (0)2 9845 1491